Trust Co. of Vermont raised its position in shares of Pfizer (NYSE:PFE) by 6.3% during the fourth quarter, Holdings Channel reports. The fund owned 271,077 shares of the biopharmaceutical company’s stock after buying an additional 16,084 shares during the quarter. Trust Co. of Vermont’s holdings in Pfizer were worth $9,818,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Peregrine Asset Advisers Inc. boosted its position in shares of Pfizer by 0.5% during the 2nd quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC raised its holdings in shares of Pfizer by 0.8% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 50 shares during the last quarter. Stone House Investment Management LLC raised its holdings in shares of Pfizer by 1.0% in the 2nd quarter. Stone House Investment Management LLC now owns 7,236 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 72 shares during the last quarter. Highland Private Wealth Management raised its holdings in shares of Pfizer by 0.8% in the 2nd quarter. Highland Private Wealth Management now owns 9,047 shares of the biopharmaceutical company’s stock worth $304,000 after acquiring an additional 76 shares during the last quarter. Finally, Autus Asset Management LLC raised its holdings in shares of Pfizer by 1.2% in the 2nd quarter. Autus Asset Management LLC now owns 6,681 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 78 shares during the last quarter. 71.21% of the stock is currently owned by institutional investors and hedge funds.
NYSE:PFE opened at $36.32 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $216,208.05, a price-to-earnings ratio of 13.71, a PEG ratio of 1.81 and a beta of 0.90. Pfizer has a 52 week low of $31.67 and a 52 week high of $39.43.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter last year, the business posted $0.47 EPS. equities analysts forecast that Pfizer will post 2.96 earnings per share for the current year.
Pfizer announced that its Board of Directors has initiated a stock buyback program on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.
In other Pfizer news, insider Mikael Dolsten sold 69,699 shares of the stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $36.59, for a total value of $2,550,286.41. Following the completion of the sale, the insider now owns 120,784 shares in the company, valued at approximately $4,419,486.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Charles H. Hill sold 42,393 shares of the firm’s stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total transaction of $1,515,973.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 248,037 shares of company stock valued at $9,064,785. Company insiders own 0.06% of the company’s stock.
A number of equities research analysts recently weighed in on PFE shares. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $37.98 target price on the stock in a report on Monday, January 8th. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, January 8th. Morgan Stanley set a $41.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Friday, January 5th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a report on Wednesday, January 17th. Finally, Sanford C. Bernstein set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, January 30th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $39.20.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/15/pfizer-pfe-shares-bought-by-trust-co-of-vermont.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.